Sai Life Sciences Limited has informed the Exchange about Transcript
SAILIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sai Life Sciences reported FY25 revenue of INR1,695 crores, up 16% YoY, with EBITDA of INR425 crores (42% growth) and margin expanding 458 bps to 25% from 20% last year. Profit after tax more than doubled to INR170 crores, a 105% increase, driven by operating leverage. The company completed INR720 crores of planned debt repayment using IPO proceeds, expecting lower interest costs from FY26. ROCE improved to 12% from 10%. FY25 capex stood at INR408 crores, with FY26 capex guided at ~INR700 crores to support manufacturing expansion and new modalities (peptides, ADCs, oligos). Large pharma share in CRO rose to 37-38% from 30%, and a INR34 crore one-time bad debt provision in Q4 impacted quarterly margins. Management reiterated its long-term EBITDA margin guidance of 28-30% within two years and 15-20% revenue CAGR over 3-5 years.
Strong FY25 results with significant margin expansion, debt reduction, and increased capex signal management's confidence in growth. The maintained 28-30% EBITDA margin target and higher FY26 capex are positive indicators for shareholders, though the one-time provision and cautious near-term biotech outlook temper near-term expectations.